We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » Biosimilars Regulation: The Importance of Interchangeability - Webinar CD/Transcript

Other Options

Audio CD/Transcript - Aug. 22, 2017

$287.00

Audio CD/Transcript - Aug. 22, 2017

$258.00

Audio CD/Transcript - Aug. 22, 2017

$244.00

Audio CD/Transcript - Aug. 22, 2017

$230.00

Audio CD/Transcript - Aug. 22, 2017

$215.00

Biosimilars Regulation: The Importance of Interchangeability - Webinar CD/Transcript

$287.00
Webinar Recordings

Product Details

Biosimilars Regulation: The Importance of Interchangeability - Decoding FDA’s Definition—and Making It Work for Your Company

The biosimilars industry is at a crossroads known as interchangeability. Drug and biologics firms that are first to master this key concept stand to reap the greatest rewards.

This presentation breaks down the concept of interchangeability into competitive terms. You’ll discover how the FDA interprets interchangeability ... what manufacturers like you need to understand… and what comes next.

Your guides are consultants Suzanne Sensabaugh and Nitisha Pyndiah, thought leaders who’ve torn apart the FDA’s key guidance known as “Considerations in Demonstrating Interchangeability with a Reference Product.” They’ll explain what the guidance says ... and what it leaves unspoken.

During the course of this 90-minute presentation, you’ll gain mastery of highly technical sticking points so important to competitive success in biosimilars, including:

  • What you think interchangeability is, vs. what the FDA thinks it is
  • The most challenging areas of product development — including technical issues of similarity in purity and potency — and how to comply
  • How the FDA evaluates immunogenicity, a key factor entailing communication and cooperation with scientific colleagues
  • The chemistry of structural features, another key factor
  • Interchangeability vs. biosimilarity: Understanding the differences
  • And much more!

The first players to master interchangeability gain a huge advantage: the grant of additional layers of exclusivity from the FDA. The subject is complex, but time is short.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing